TGNA Stock Chart & Stats
€1.32
€0.08(12.28%)
At close: 4:00 PM EST
€1.32
€0.08(12.28%)
Day’s Range― - ―
52-Week Range€0.60 - €1.49
Previous CloseN/A
Volume0.00
Average Volume (3M)37.00
Market Cap
€202.03M
Enterprise Value€108.26M
Total Cash (Recent Filing)€92.84M
Total Debt (Recent Filing)€2.18M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding278,559,940
10 Day Avg. Volume111
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€7.63M
Bulls Say, Bears Say
Bulls Say
Oncology Immunotherapy FocusA dedicated focus on oncology immunotherapies gives Transgene a clear strategic identity in a large, clinically important market. Its therapeutic-vaccine and immune-based approach can support differentiated development programs and create multiple opportunities for future product validation.
Platform-Based PipelineThe combination of viral-vector platforms and individualized vaccine concepts provides a reusable technological foundation rather than a single-product strategy. Applying these approaches across several solid tumors may diversify clinical opportunities and improve the potential value of successful development outcomes.
Low Financial LeverageVery low leverage reduces the immediate burden of interest and debt repayment compared with a highly indebted biotechnology company. The sizable equity base provides a stronger financial foundation for continuing research and development, although it does not eliminate the need to manage ongoing funding requirements.
Bears Say
Persistent Losses And Revenue DeclineSevere revenue deterioration alongside continuing operating and net losses indicates that the current business has not yet established a sustainable commercial earnings base. Deeply negative margins leave Transgene dependent on future pipeline progress to offset its cost structure and improve financial performance.
Ongoing Cash BurnPersistent negative operating and free cash flow means research and development activities are consuming cash rather than funding themselves through operations. This reduces financial flexibility over the next several quarters and makes continued access to external capital important for maintaining the development pipeline.
Funding And Dilution RiskMaterially negative shareholder returns and substantial historical changes in equity indicate that capital efficiency remains weak and financing needs may continue. Reliance on equity funding can dilute existing shareholders, while recurring losses make it harder to build durable value without successful clinical or commercial progress.
Transgene News
TGNA FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.60 and its highest was €1.49 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €202.03M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Nov 09, 2026 which is in 9 days.
How were Transgene SA’s earnings last quarter?
Transgene SA released its earnings results on Sep 24, 2026. The company reported -€0.057 earnings per share for the quarter.
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Transgene SA reported an EPS of -€0.057 in its last earnings report. Following the earnings report the stock price went down -1.083%.
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in DE:TGNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―